Imran Sheriff, MD
Family Medicine · Reno, NVNPI 1659373678
Payments from drug & device makers
Across 508 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- AbbVie$1K
- Astellas Pharma US Inc$913
- Boehringer Ingelheim$660
- Pfizer$535
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,68194%
- Education$6126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $2,044 |
| AstraZeneca | 84 | $1,898 |
| AbbVie(2 entities) | 78 | $1,349 |
| Astellas Pharma US Inc | 28 | $913 |
| Boehringer Ingelheim | 29 | $660 |
| Pfizer | 24 | $535 |
| Bayer | 28 | $495 |
| Amgen(2 entities) | 23 | $345 |
| Sanofi-aventis U.S. LLC | 13 | $304 |
| Abbott | 21 | $230 |
| Lilly USA, LLC | 9 | $210 |
| Novo Nordisk | 10 | $187 |
| Novartis | 7 | $138 |
| Johnson & Johnson | 4 | $105 |
| Exact Sciences | 4 | $99 |
| Sanofi Pasteur Inc. | 3 | $72 |
| Idorsia Pharmaceuticals US Inc | 3 | $66 |
| Ironwood Pharmaceuticals, Inc | 3 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Eisai Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Vertex | 2 | $49 |
| Medtronic | 2 | $44 |
| Redhill Biopharma Inc. | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Boston Scientific | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Merck | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Harmony Biosciences LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
How this compares
$10,292 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $345,581 |
| JardianceEmpagliflozin | 211 | $318,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $266,098 |
| TradjentaLinagliptin | 183 | $232,761 |
| EliquisApixaban | 144 | $191,985 |
| FarxigaDapagliflozin Propanediol | 111 | $140,706 |
| JanuviaSitagliptin Phosphate | 88 | $107,250 |
| MounjaroTirzepatide | 56 | $82,962 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 64 | $68,418 |
| CreonLipase/Protease/Amylase | 28 | $67,636 |
| XareltoRivaroxaban | 52 | $65,891 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $56,302 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $55,567 |
| LinzessLinaclotide | 43 | $50,712 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $47,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat, Stiolto Respimat | $660 | $650,837469 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,044 | $382,261306 claims |
| Novo NordiskOzempic | $187 | $345,581190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,898 | $206,764177 claims |
| PfizerEliquis | $535 | $191,985144 claims |
| AbbVieCreon, Linzess | $1,349 | $118,34771 claims |
| Lilly USA, LLCMounjaro, Trulicity | $210 | $117,80674 claims |
| MerckJanuvia | $24 | $107,25088 claims |
| Johnson & JohnsonXarelto | $105 | $65,89152 claims |
| Astellas Pharma US IncMyrbetriq | $913 | $45,33445 claims |
| BayerKerendia | $495 | $37,41223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Reno
- Susan ParkReno$1.1M
- Bayo Curry-WinchellReno$74K
- Catherine McCarthyReno$68K
- Francisco DofelizReno$30K
- Michael ObrienReno$18K
- James McLennanReno$16K
- Jeremy BearfieldReno$15K
- Ricardo GonzalezReno$11K
- Jennifer HornbackReno$11K
- Ambika UppuReno$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.